Dianthus Therapeutics (NASDAQ:DNTH) EVP Simrat Randhawa Sells 23,124 Shares of Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Simrat Randhawa sold 23,124 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $106.41, for a total transaction of $2,460,624.84. Following the sale, the executive vice president owned 4,000 shares of the company’s stock, valued at approximately $425,640. This represents a 85.25% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Dianthus Therapeutics Stock Performance

Shares of Dianthus Therapeutics stock opened at $107.85 on Friday. The company has a market capitalization of $5.90 billion, a P/E ratio of -25.99 and a beta of 1.24. Dianthus Therapeutics, Inc. has a 1 year low of $23.70 and a 1 year high of $117.88. The company’s fifty day moving average is $104.98 and its two-hundred day moving average is $88.94.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The business had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $0.30 million. As a group, equities analysts expect that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current year.

Wall Street Analysts Forecast Growth

DNTH has been the topic of several analyst reports. Wedbush lifted their target price on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Wall Street Zen upgraded Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Truist Financial increased their price target on Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. HC Wainwright lifted their price objective on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Finally, TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $124.27.

Institutional Trading of Dianthus Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in DNTH. Raymond James Financial Inc. purchased a new stake in Dianthus Therapeutics during the second quarter worth about $27,000. First Horizon Corp acquired a new stake in shares of Dianthus Therapeutics during the 1st quarter valued at approximately $32,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at approximately $40,000. EFG International AG purchased a new stake in shares of Dianthus Therapeutics during the 2nd quarter worth approximately $49,000. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Dianthus Therapeutics during the 3rd quarter worth approximately $64,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.